Sam Fazeli

Yeah, absolutely.

Now, in terms of the drug that I forgot, it's Fresenio, of course.

So we have Fresenio, Ibrans, and Kiskali in the CDK4-6 inhibitors.

And Fresenio is Lily's, Kiskali is Novartis, and Ibrans is Pfizer.

Yes, sorry, I should...

Yes, that's right.

Oh, yeah.

Well, you know, I'm in England.

So I come up with my own pronunciation for stuff.

For sure.

Well, and they've been becoming very good at it, even better recently, making it major tongue twisters.

So let's touch on very quickly on HLX43.

We saw some data at WCLC for this agent, which is an antibody drug conjugate targeting PD-L1.

I am slightly biased towards drugs that use PD-L1 for a targeting agent.

methodology which of course from it you get kind of a double whammy you get potentially tumor targeting but of course PD-L1 is not just tumor cell expressed and you also get inhibition of PD-L1

So you get a double whammy in there, whereas if you just use a PD-1, in fact, you clearly risk killing the T-cells.

Talk to us a little bit about this agent and what your hopes are.

Here you're in a slightly different setup, recurrent metastatic esophageal carcinoma, squamous carcinoma, and actually advanced non-small cell lung cancer.

So talk to us a little bit about where this is going and where your hopes are.

Well, we're certainly watching it.